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Abstract 42 
Purpose: Physical overexertion can lead to detrimental 43 
overreaching states without sufficient recovery, which may be 44 
identifiable by blunted exercise-induced cortisol and 45 
testosterone responses. A running test (RPETP) elicits 46 
reproducible plasma cortisol and testosterone elevations (in a 47 
healthy state) and may detect blunted hormonal responses when 48 
overreached. This current study determines the salivary cortisol 49 
and testosterone responses reproducibility to the RPETP, to 50 
provide greater practical validity using saliva compared to the 51 
previously utilized blood sampling. Secondarily, the relationship 52 
between the salivary and plasma responses will be assessed. 53 
Methods: Twenty-three active, healthy males completed the 54 
RPETP on three occasions. Saliva (N=23) and plasma (N=13) 55 
were collected Pre-, Post- and 30 min Post-Exercise. Results: 56 
Salivary cortisol did not elevate in any RPETP-trial, and reduced 57 
concentrations occurred 30 min Post-Exercise (P = 0.029, η2 = 58 
0.287); trial differences were observed (P < 0.001, η2 = 0.463). 59 
The RPETP elevated (P < 0.001, η
2 = 0.593) salivary testosterone 60 
with no effect of trial (P = 0.789, η2 = 0.022). Intra-individual 61 
variability was 25% in cortisol and 17% in testosterone. ‘Fair’ 62 
ICCs of 0.46 (cortisol) and 0.40 (testosterone) were found. 63 
Salivary and plasma cortisol positively correlated (R = 0.581, P 64 
= 0.037) yet did not for testosterone (R = 0.345, P = 0.248). 65 
Conclusions: The reproducibility of salivary testosterone 66 
response to the RPETP is evident and supports its use as a 67 
potential tool, subject to further confirmatory work, to detect 68 
hormonal dysfunction during overreaching. Salivary cortisol 69 
responds inconsistently in a somewhat individualized manner to 70 
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Effective physical performance adaptations require an 82 
appropriately prescribed and periodized training program.1 83 
When overreaching occurs, a reduced athletic capacity 84 
(transiently or otherwise) may be observed, due to imbalanced 85 
overload and recovery periodisation.2 Appropriate recovery may 86 
elicit a “supercompensatory” performance response referred to 87 
as functional overreaching (FOR).3 Yet, insufficient recovery 88 
from prolonged periods of intensified-training may lead to “non-89 
functional overreaching” (NFOR) requiring weeks/months for 90 
full recovery – whilst – unchecked NFOR can progress to 91 
overtraining syndrome (OTS) which can, on occasions, demand 92 
years for full recovery to occur.4 Prevalence of NFOR/OTS 93 
during an elite athlete’s career can range from ~35%5 to 67%6 94 
yet little progress has been made regarding objective biomarkers 95 
that detect the onset/magnitude of overreaching.3 96 
 97 
Resting cortisol and testosterone concentrations have been 98 
proposed as overreaching/OTS markers, as they provide a ratio 99 
of catabolic to anabolic activity.3 However, their alterations at 100 
rest are inconsistent when comparing pre to post periods of 101 
overload.7,8 Recently, their acute responses to exercise have 102 
shown promise as an indicator of hormonal dysfunction 103 
following intensified-training periods.9,10 Blunted exercise-104 
induced salivary cortisol and testosterone responses were shown 105 
following a 30-min cycling bout, known as the 55/80 [1 min at 106 
55% maximal workload (?̇?max) and 4 min at 80% ?̇?max] 107 
following an 11-day9 and a 10-day10 intensified-training period, 108 
suggesting these exercise-induced salivary hormones are 109 
potentially useful biomarkers of overreaching/OTS. Recently, a 110 
treadmill-derivative [rating of perceived exertion protocol 111 
(RPETP)]
11 of the 55/80 cycle12 was developed and shown to 112 
induce reproducible elevations of plasma testosterone but not 113 
cortisol.11  114 
 115 
Therefore, this study primarily sought to, in attempt to increase 116 
practical validity, determine whether the same RPETP cortisol 117 
and testosterone responses in plasma11 could be replicated in 118 
salvia, in healthy (i.e. non-overreached) adult, male individuals. 119 
If salvia was to show such validity, the RPETP could become a 120 
more practical tool to detect and subsequently inform 121 
practitioner decision-making, regarding any potential hormonal 122 
dysregulation associated with overreaching/OTS. Secondarily, 123 
this study also intended to assess the relationship between saliva 124 
and blood cortisol and testosterone responses to the RPETP, albeit 125 
in a subsection of previously measured participants. It was 126 
hypothesised that (i) salivary testosterone but not cortisol would 127 
acutely elevate in response to the RPETP; (ii) these responses 128 
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would be reproducible; and (iii) the salivary hormone responses 129 






This study was completed to expand upon previously published 136 
data.11 Twenty-three ‘recreationally-trained’ and ‘trained’ 137 
(categorised as per13 and reflective of performance levels 2 and 138 
3) males [age 21 ± 2 years; height 177 ± 6 cm; body mass 76.1 139 
± 13.1 kg; maximal heart rate (HRmax) 191 ± 9 beats·min
-1; 140 
maximum oxygen uptake (V̇O2max) 55 ± 6 mL·kg
-1·min-1] 141 
volunteered to participate in this study. Partial data from thirteen 142 
participants from the previously published study11 143 
(physiological, plasma cortisol, plasma testosterone and 144 
anthropometric data) are included in the present study. The study 145 
was conducted in accordance with the 2013 Declaration of 146 
Helsinki under ethical approval [University of Bedfordshire 147 
Research Ethics Committee (2014ISPAR003)]. Following 148 
verbal and written study descriptions participants provided 149 




The original research11 examined the reproducibility of plasma 154 
cortisol and testosterone responses to two novel running 155 
protocols. The present study extends this work11 by examining 156 
salivary cortisol and testosterone responses to one of these 157 
running protocols (RPETP), given saliva is a more ecologically 158 
valid sample compared to plasma. 159 
 160 
Participants undertook 5 main trials within a temperature-161 
controlled laboratory (see Figure 1). On the first visit, a 162 
submaximal running test followed by a V̇O2max test was 163 
undertaken to physiologically characterise participants. During 164 
the subsequent 4 visits (separated by a minimum of 4 to 7 days), 165 
3 exercise trials (T1, T2 and T3), and one resting control trial 166 
(CTL) were completed. In each exercise trial, participants 167 
undertook the RPETP (Figure 1), which has been detailed 168 
previously.11 CTL identified the influence of the circadian 169 
rhythm on the hormones measured.14,15 All participants woke 170 
before 8 AM on the morning of the trial which started at 12 PM 171 
for diurnal variation control purposes.16 A 76-statement 172 
recovery-stress questionnaire (RESTQ-7617) was completed 173 
before the start of each exercise bout, as used previously11. No 174 
differences in RESTQ-7617 metrics were observed prior to trial 175 
completion, indicating the participants’ were in a similar state of 176 
well-being and pre-disposition to exercise prior to all trials, 177 
likely not overreached and that any alterations in the hormones 178 
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examined were not due to pre-trial stress and/or well-being (or 179 
variation in said measures pre-trial). 180 
 181 
Abstinence from exercise, caffeine and alcohol intake 24 hours 182 
before each main trial was requested, and a standard breakfast 183 
chosen by the participant was consumed by 9 AM (repeated prior 184 
to each visit). The participants’ pre-trial 24 h nutritional intake 185 
was determined via a weighed food diary. Nutrition analysis 186 
software (Dietplan, Version 6.70.74, Forestfield, West Sussex, 187 
UK) was used on the food diaries and mean energy (9851 ± 4182 188 
kJ), carbohydrate (56% ± 12%), fat (25 % ± 13%), and protein 189 
(17% ± 2%) intake were determined. Euhydration was 190 
confirmed by a urine osmolality of ≤ 700 mOsm.kg.H2O
-1.18 191 
Food consumption was not allowed until the end of each main 192 
experimental trial but water was provided ad libitum up to 10 193 
min before saliva sample collection.  194 
 195 




Submaximal running and ?̇?𝑶𝟐𝒎𝒂𝒙 tests. The protocols used for 200 
determination of V̇O2max have been detailed and justified in 201 
previous research.11,19 Briefly, a 4x4-min-stage, incremental 202 
treadmill-run submaximal test was completed, to determine the 203 
running speed/oxygen consumption (V̇O2) relationship.
20 The 204 
initial speed was self-selected between 6.5 – 12.0 km.h-1 and 205 
increased by 1 km.h-1 every stage. The speed corresponding to a 206 
HR of ~150 beats.min-1 (range: 8.0 – 14.0 km.h-1) on the 207 
submaximal test was noted and, after a 20-min recovery period, 208 
used on the incline-ramped V̇O2max test.
11,20 The speed was 209 
maintained throughout with a 1% increase in gradient every 210 
minute until volitional exhaustion. Expired gas was analysed 211 
through a breath-by-breath ergospirometry system (MetaLyzer 212 
3B, Cortex, Leipzig, Germany). This protocol determines the 213 
velocity at V̇O2max (vV̇O2max), from which percentages were 214 
used in the original study11. Such inferences were not required 215 
for this study as only the self-paced RPETP protocol was utilized. 216 
The participants’ V̇O2max was established in accordance with the 217 
British Association of Sports and Exercise Sciences’ criteria.19 218 
 219 
RPETP and CTL: Briefly and as described in full previously
11, 220 
the RPETP is a self-paced, continuous, 30-min running bout, with 221 
alternating blocks of 1 min at 11 (fairly light) and 4 min at 15 222 
(hard) on the 6-20 Borg scale21. Speed was self-adjusted to 223 
maintain exertion in the target range and blinded from the 224 
participant to maintain the exertion in the target range. Saliva 225 
samples were collected pre-, immediately post-, and 30 min post-226 
exercise in all exercise trials. The CTL followed the same 227 
scheme as in Figure 1 for the RPETP, but no exercise was 228 
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completed, therefore sample timepoints are referred to as pre-229 
CTL, post-CTL and 30 min post-CTL. Blood samples were also 230 
collected in the first 13 participants immediately before saliva 231 
sampling. Heart rate (HR) and RPE were measured in the last 232 
15s of each stage via short-range radio telemetry (Polar FT1, 233 
Polar Electro Oy, Kempele, Finland) and the 6-20 Borg scale,21 234 
respectively. 235 
 236 
Saliva handling and analysis: Saliva samples were collected 237 
into 7 mL polystyrene sterile containers (Sterilin, Thermo 238 
Scientific, Loughborough, UK) by unstimulated passive drool, 239 
with eyes closed, head tilted slightly forward and avoiding any 240 
orofacial movement.22 Water consumption was not allowed 241 
within the 10 min preceding sampling. Minimum collection time 242 
was 3 min for each participant to allow for collection of 243 
sufficient sample volume (~2 mL). Samples were then 244 
centrifuged at 14600 g for 10 min (Espresso Microcentrifuge, 245 
Thermo Scientific, Loughborough, UK) and the supernatant was 246 
transferred into 1.5 mL aliquots (Eppendorf, Hamburg, 247 
Germany) to be stored at -80°C until further analysis. 248 
 249 
Salivary cortisol and testosterone concentrations were 250 
determined by using commercially available enzyme-linked 251 
immunosorbent assay (ELISA) kits (Salimetrics, PA 16803, 252 
USA). All samples were analysed in duplicate and average 253 
concentrations were used. The determined mean intra-assay CVs 254 
were 4.8% (salivary cortisol) and 4.4% (salivary testosterone). 255 
The present analyses resulted in in-lab mean inter-assay CVs of 256 
5.1% and 6.8% for salivary cortisol and testosterone, 257 
respectively. 258 
 259 
Venous plasma handling and analysis: All analytical 260 
procedures for blood collection, treatment and analysis have 261 
been detailed previously.11 Briefly, whole blood samples were 262 
collected by venepuncture from the antecubital fossa into 263 
tripotassium ethylenediaminetetraacetic acid (K3EDTA) tubes, 264 
centrifuged at 4ºC for 10 min (1500g) and the plasma stored at -265 
80ºC before further analysis. The ELISA kits (IBL International, 266 
Hamburg, Germany) mean intra- and inter-assay CVs were 3.0% 267 
and 4.6%, and 3.5% and 5.7% for plasma cortisol and 268 
testosterone, respectively. The venous blood sample data was 269 
taken from previously published work11 and has been used for 270 
correlation with the salivary data presented in this present study 271 
only. 272 
 273 
Statistical Analysis 274 
 275 
The IBM Statistical Package for Social Sciences® (SPSS) 276 
Statistics version 23.0 (SPSS Inc., Chicago, IL) was used for all 277 
statistical analysis. The Shapiro-Wilk test and scatter plots were 278 
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used for verification of normality and homoscedasticity of raw 279 
data, respectively. When non-normally distributed (all 280 
variables), log transformation to base 10 was completed with 281 
subsequent normality rechecked. All data were then deemed 282 
normally distributed, except for speed (how this analysis was 283 
completed is detailed below). Magnitude of effect was examined 284 
using the Cohen’s d effect sizes (ES)23, determined by hand as 285 
described in Vincent and Weir,24 and labeled using consistent 286 
thresholds of < 0.2 trivial, 0.21 – 0.49 small, 0.50 – 0.80 287 
moderate, > 0.80 large.24,25 The alpha level of significance was 288 
set as P < 0.05. Data is reported as mean (SD), and all results are 289 
presented as raw data to facilitate comprehension. Salivary 290 
cortisol and HRmax data were collapsed for all correlation 291 
analysis. 292 
 293 
Salivary Hormone and Physiological Data Analysis: Salivary 294 
testosterone, speed and HR data sets were collapsed given there 295 
were no significant differences between any trial (excluding 296 
CTL) (P > 0.05). Salivary cortisol was not collapsed as a trial 297 
effect was observed. A two-way repeated measures analysis of 298 
variance (ANOVA) was used on the normalised data (salivary 299 
hormones and HR), with unchanged significant effects observed. 300 
On finding an effect, paired sample t-tests were used, and 301 
Bonferroni adjustments applied (also used to examine the 302 
hormonal responses during CTL), with partial eta squared (η2) 303 
values determining the size of the effect. A non-parametric 2-304 
related sample Wilcoxon test was used for between-trial 305 
comparisons for speed. 306 
 307 
Reproducibility Analysis: Intra-individual coefficients of 308 
variation (CVi) for all physiological and hormonal 309 
measurements were calculated. The intra-individual mean 310 
concentrations (X̅t) and SDs (SDt) were used to calculate the CVi 311 
using the equation CVi = (SDt/X̅t)*100. A two-way model based 312 
on the examination of single measures intraclass correlation 313 
coefficient (ICC2,1) was also used on the collapsed data to 314 
account for the between-individual variability.27 Guidelines on 315 
ICC models propose that values considered poor sit below 0.40, 316 
whereas fair sit within 0.40-0.59, good between 0.60-0.74, and 317 
excellent if or above 0.75.28 318 
 319 
Correlation Analysis: Pearson’s correlation was used to 320 
determine the correlation between the salivary and plasma 321 
cortisol and testosterone concentrations, and the individual 322 
absolute change in salivary cortisol and testosterone with HRmax. 323 
As there was no change in the cortisol response to exercise, these 324 
data have been collapsed. The correlation between plasma and 325 
salivary testosterone has been examined at pre-, post- and 30 min 326 






Acute Hormonal Responses 332 
 333 
All reproducibility data and average salivary 334 
cortisol/testosterone concentrations are presented in Table 1. 335 
 336 
*** Insert Table 1 near here ***  337 
 338 
Salivary cortisol. A trial effect was observed (P < 0.001, η2 = 339 
0.463), with average responses being lower in T3 compared to 340 
T2 (P = 0.002). A time effect (P = 0.029, η2 = 0.287) was also 341 
observed. Pairwise comparisons showed cortisol did not acutely 342 
elevate in any exercise trial (ES = 0.10 in T1, ES = -0.11 in T2, 343 
ES = 0.02 in T3, all P > 0.05), but a lower concentration was 344 
observed at 30 min post-exercise when compared to post-345 
exercise in T1 (P = 0.003, ES = 0.32) and T2 (P = 0.043, ES = 346 
0.11). Individual acute responses are presented in Figure 2. 347 
 348 
Salivary testosterone. There was no effect of trial (P = 0.789, η2 349 
= 0.022), but a significant time effect was observed (P < 0.001, 350 
η2 = 0.593). Pairwise comparisons showed salivary testosterone 351 
acutely elevated (P < 0.001) and remained elevated at 30 min 352 
post-exercise (P < 0.05) in all exercise trials. Average acute 353 
percentage-elevations were ~23% (ES = -0.94) in T1, ~40% (ES 354 
= -1.10) in T2 and ~32% (ES = -0.87) in T3. Individual exercise-355 
induced changes are presented in Figure 2. 356 
 357 
Plasma cortisol and testosterone. The plasma cortisol and 358 
testosterone values can be examined in detail elsewhere.11 359 
Briefly, average raw data for plasma cortisol (nmol.L-1) was 360 
259.1 ± 105.3, 313.9 ± 125.8, and 292.7 ± 123.2 at pre-, post-, 361 
and 30 min post-exercise, respectively. The average raw data for 362 
plasma testosterone (nmol.L-1) was 13.4 ± 2.6, 18.9 ± 3.7, and 363 
15.0 ± 3.2 at pre-, post-, and 30 min post-exercise, respectively.  364 
 365 
Plasma and Salivary Hormone Correlation. Plasma and salivary 366 
cortisol were shown to positively correlate (R = 0.581, P = 367 
0.037). However, no correlation was observed between plasma 368 
and salivary testosterone concentration levels at pre-exercise (R 369 
= 0.430, P = 0.143), post-exercise (R = 0.250, P = 0.409), and 370 
30 min post-exercise (R = 0.340, P = 0.256), as presented in 371 
Figure 3. 372 
 373 
*** Insert Figure 2 near here *** 374 
 375 
*** Insert Figure 3 near here *** 376 
 377 
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Individual Absolute Change in Salivary Hormone and 378 
Physiological Responses Correlation. Salivary cortisol and 379 
HRmax were shown to positively correlate (R = 0.632, P < 0.001). 380 
A correlation between salivary testosterone and HRmax was not 381 
observed (R = 0.094, P = 0.671), as presented in Figure 4. 382 
 383 
*** Insert Figure 4 near here *** 384 
 385 
Hormonal Responses During CTL 386 
 387 
Salivary cortisol concentrations were lower at post-CTL and 30 388 
min post-CTL than Pre-CTL by ~28% ± 17% and ~37% ± 19%, 389 
respectively (both P < 0.001). Pre-CTL salivary testosterone was 390 
not different from post-CTL (P = 0.142) but was ~12% ± 5% 391 
higher than 30 min post-CTL (P = 0.003) (Table 1). 392 
 393 
*** Insert Figure 5 near here *** 394 
 395 
Speed/HR Acute Responses and Urine Osmolality 396 
No differences between collapsed trials were found in speed or 397 
HR (P > 0.05 for all) (see Figure 5). Reproducibility and average 398 
data for speed and HR in response to the RPETP trials are 399 
presented in Table 1. Urine osmolality did not differ between 400 





This study’s primary aim was to determine whether the same 406 
RPETP cortisol and testosterone responses in plasma
11 could be 407 
replicated in saliva, in healthy (i.e. non-overreached) adult, male 408 
individuals. Indeed, the RPETP significantly and acutely elevated 409 
salivary testosterone in T1 (515 to 630 pmol·L-1, ES = -0.94), T2 410 
(491 to 663 pmol·L-1, ES = -1.10), and T3 (523 to 661 pmol·L-1, 411 
ES = -0.87). However, salivary cortisol did not significantly 412 
elevate in any trial, as shown previously elsewhere11, thus 413 
accepting hypothesis (i). Furthermore, the CVi in salivary 414 
testosterone observed in this present study (17 ± 7%) is similar 415 
to the exercise-induced variance observed for plasma 416 
testosterone elsewhere (12 ± 9%)11. This has not been observed 417 
for salivary cortisol (25 ± 15%), whose variability in plasma to 418 
the RPETP is moderately lower (12 ± 7%)
11, partially accepting 419 
hypothesis ii). The secondary aim sought to assess the 420 
relationship between saliva and blood cortisol and testosterone 421 
responses to the RPETP, albeit in a subsection of previously 422 
measured participants. A correlation between salivary and 423 
plasma testosterone levels was not observed (see Figure 3). 424 
Whilst salivary cortisol and plasma surrogates did correlate, their 425 
lack of change across trials limits the utility in this cortisol 426 
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specific inference. Taken together (cortisol and testosterone 427 
correlations) the data rejects hypothesis (iii). 428 
 429 
Previous data demonstrates a correlation between plasma and 430 
salivary testosterone29,30 – however – this is in resting samples 431 
unlike the ‘exercise response’ data from the present study (see 432 
Figures 2 and 3, and Table 1). Similarly, Hough et al. (2011)12 433 
did not observe a correlation in exercise-induced responses of 434 
plasma and salivary testosterone, although the authors suggest 435 
caution is required when interpreting their data. Specifically, 436 
they12: (i) missed some post-exercise blood samples; and (ii) 437 
proposed that the correlation between plasma and salivary 438 
testosterone might not have occurred as testosterone elevates to 439 
exercise stress quicker in the blood than saliva. Indeed, it has 440 
been observed elsewhere that despite parallel increases in blood 441 
and saliva testosterone after oral testosterone undecanoate 442 
administration in healthy men, the absorption curves showed a 443 
high interindividual variability in the time at which maximum 444 
concentrations were reached.31  445 
 446 
Furthermore, Fiers et al. (2014)32 have observed that salivary 447 
testosterone concentrations were not identical to comparable 448 
serum free testosterone due to testosterone binding with salivary 449 
proteins. In this present study, we speculate that the correlation 450 
may not have been observed due to timing of the testosterone 451 
entering the saliva. Supporting our speculation, we have 452 
observed that post-exercise plasma testosterone correlates only 453 
with the 30 min post-exercise salivary testosterone in T1 (data 454 
not presented). However, it should be noted that salivary 455 
testosterone significantly increased in response to the RPETP in 456 
all trials, and that the intra-individual variability in the present 457 
study was 17 ± 7%. Importantly, this present exercise-induced 458 
variability in salivary testosterone (17 ± 7%) is noticeably lower 459 
than the 37% blunted elevation in cycling-induced salivary 460 
testosterone responses after an 11-day period of intensified  461 
training (compared with a mean ~58% elevation pre-training) in 462 
active males suspected to be overreached.9 Suggesting the RPETP 463 
may be useful when measuring testosterone responses in the 464 
saliva of healthy male individuals. 465 
 466 
A mean increase in salivary cortisol was not present, yet some 467 
participants demonstrated an increase at the individual level (see 468 
Figure 2 and Table 1; although responses are not replicated 469 
across trials at the level of the individual), likely due to exercise 470 
intensity variability between participants. Indeed, positive 471 
correlations between HRmax observed during the RPETP and 472 
absolute change values in salivary cortisol were observed (see 473 
Figure 4). Cortisol has been reported to acutely elevate in 474 
response to exercise.12,33 Although it has been proposed that 475 
exercise must be at an intensity above 60% V̇O2max for at least 476 
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20-30 min to induce an elevation in cortisol levels,34 this is not 477 
always observed.35  As no acute elevation and a between-trial 478 
difference was observed, the RPETP may not have provided a 479 
sufficient physiological strain to activate an exercise-induced 480 
salivary cortisol response in all participants; as also observed in 481 
its plasma surrogate.11 These data may suggest that the 482 
variability observed in the salivary cortisol sensitivity to exercise 483 
may be driven by exercise intensity. However, no correlation 484 
was present between salivary testosterone and HRmax (see Figure 485 
4) despite a consistent elevation in this hormone in response to 486 
the RPETP and low inter- (see Figure 2, row D) and intra-487 
individual (Table 1) variability. The data reinforces the highly-488 
sensitive nature of salivary testosterone to exercise (certainly in 489 
response to the RPETP, as observed elsewhere in its plasma 490 
surrogate11), highlighting its potential utility within 491 
hypothalamic-pituitary-gonadal dysregulation associated with 492 
NFOR/OTS. 493 
 494 
Practical Applications 495 
 496 
• Salivary testosterone is sensitive and a reproducible 497 
biomarker to the RPETP indicating a triggered activation of 498 
the hypothalamic-pituitary-gonadal complex after short-499 
duration, high-intensity running exercise. 500 
• Salivary cortisol demonstrates a somewhat individualized 501 
yet non-sensitive response to the RPETP and from the present 502 
and related experimental designs, is currently an unproven 503 
biomarker-related exercise-induced stress responsiveness. 504 
• The RPETP elicits reproducible physiological and salivary 505 
testosterone hormone responses with greater practical 506 
application/integration than previous methods (e.g. saliva 507 
and not plasma samples); with further proof of concept (i.e. 508 
analysis of the effects of a period of intensified training on 509 
the RPETP-induced responsiveness of salivary testosterone) 510 




Physiological responses (HR and speed at prescribed RPE) were 515 
shown reproducible across all RPETP trials within the present 516 
study; within a larger sample than used previously elsewhere.11 517 
Salivary cortisol was not sensitive to the RPETP (as shown 518 
elsewhere albeit in plasma surrogates11). Despite cortisol 519 
salivary levels correlating with its plasma surrogate as 520 
hypothesised, acute cortisol responses may be influenced by 521 
diurnal variation and an individualised response to RPETP (likely 522 
exercise intensity driven), rendering it an unreliable biomarker 523 
to highlight exercise responsiveness, within the present design. 524 
The present RPETP data suggests salivary testosterone to be a 525 
more robust marker of a triggered endocrine mobilization during 526 
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exercise. Yet, and despite no strong correlation observed in the 527 
exercise-induced salivary and plasma testosterone levels, the 528 
variability between the acute responses of plasma and salivary 529 
testosterone to the RPETP are relatively similar. Therefore, the 530 
consistent and sensitive exercise responsiveness of salivary 531 
testosterone to the RPETP suggest: (i) greater utility than cortisol; 532 
(ii) a more practically compatible bio-sample than plasma; and 533 
(iii) changes in salivary testosterone were no due to inconsistent 534 
physiological strain. Nevertheless, future work is required to 535 
detail proof of concept regarding the salivary testosterone 536 
sensitivity to the RPETP in an active population following a 537 
period of intensified training. Such data would demonstrate 538 
quantitively whether RPETP-induced salivary (and plasma) 539 
testosterone responses and their blunting, are a suitable tool to 540 
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Figure Captions 699 
 700 
Figure 1 Schematic presentation of (A) the experimental trial 701 
day protocol and procedures, (B) the study design, and (C) the 702 
RPETP design; Submax, submaximal treadmill-run test; V̇O2max, 703 
maximal oxygen uptake test; CTL, control resting trial. 704 
 705 
Figure 2 Salivary hormone responses to the RPETP and CTL 706 
protocols at Pre-Exercise (Pre-CTL), Post-Exercise (Post-CTL) 707 
and 30 min Post-Exercise (30 min Post-CTL): (A) Salivary 708 
cortisol; (B) Salivary testosterone; (C) Individual absolute 709 
changes in salivary cortisol; (D) Individual absolute changes in 710 
salivary testosterone. 711 
#Trial difference (T3 different than T2). *Different than Pre-712 
exercise values (P < 0.01). **Different than Pre-exercise values 713 
(P < 0.05). ‡Different than Post-exercise values (P < 0.05). 714 
†Different than CTL (P < 0.01). δ - small effect size for trial; ✥ 715 
- trivial effect size for trial. 716 
 717 
Figure 3 Collapsed salivary and plasma cortisol correlation (A), 718 
and salivary and plasma testosterone correlation analysis at pre-719 
exercise (B), post-exercise (C), and 30 min post-exercise (D). 720 
 721 
Figure 4 Correlation analysis between HRmax observed during 722 
RPETP and collapsed individual absolute changes in salivary 723 
cortisol (top) and salivary testosterone (bottom). 724 
 725 
Figure 5 Heart rate and speed responses to the RPETP on each 726 























Table Captions 749 
 750 
Table 1 Average raw data for urine osmolality, the physiological 751 
and hormone responses in the CTL, T1, T2 and T3 bouts and 752 
reproducibility data (when applicable) data for T1, T2 and T3 753 
only. 754 
 755 
